Abstract

This paper introduces the concept of personalized physiological medicine that is specifically directed at the needs of the critically ill patient. This differs from the conventional view of personalized medicine, characterized by biomarkers and gene profiling, instead focusing on time-variant changes in the pathophysiology and regulation of various organ systems and their cellular and subcellular constituents. I propose that personalized physiological medicine is composed of four pillars relevant to the critically ill patient. Pillar 1 is defined by the frailty and fitness of the patient and their physiological reserve to cope with the stress of critical illness and therapy. Pillar 2 involves monitoring of the key physiological variables of the different organ systems and their response to disease and therapy. Pillar 3 concerns the evaluation of the success of resuscitation by assessment of the hemodynamic coherence between the systemic and microcirculation and parenchyma of the organ systems. Finally, pillar 4 is defined by the integration of the physiological and clinical data into a time-learning adaptive model of the patient to provide feedback about the function of organ systems and to guide and assess the response to disease and therapy. I discuss each pillar and describe the challenges to research and development that will allow the realization of personalized physiological medicine to be practiced at the bedside for critically ill patients.

Background

Randomized controlled clinical trials (RCTs) have failed to provide needed direction for the diagnosis and treatment of the critically ill patient. Such trials, based on the idea that evidence for the treatment of individual patients can only be achieved by demonstrating efficacy of one treatment modality over another in large groups of patients, have not been able to demonstrate effective therapies; at best, the trials (e.g., TRIC, SPLIT, SAFE, PROCESS, ARISE, CHEST, PROWESS, SEPSISPAM, etc.) have shown no difference between groups. These results often lead, in practice, to the mistaken conclusion that there is no difference between the interventions. A more correct conclusion could be that such RCTs, by design, are unable to demonstrate differences in heterogeneous intensive care patients because the physiology of individual patients at the bedside indeed shows differences between various interventions. These shortcomings of RCTs have led to the suggestion that such trials should be abandoned to focus on a more personalized approach for identifying the optimal therapy for each individual patient [1]. This concept has been referred to as “personalized medicine” and has been mainly associated with the measurement of pharmacological biomarkers and genetic profiling with the goal of identifying personalized therapy to result in improved survival benefit (e.g., [2]). However, additional requirements and concepts may be needed for personalized medicine if this concept is to be applied to the critically ill patient. The time-variant changes in (patho)physiology in response to the wide range of disorders with complex interactions between failing organ systems being treated with a variety of drugs and organ-supporting devices distinguishes critically ill patients from other categories of patients (e.g., oncology and cardiology). These considerations lead to the idea that a new form of personalized medicine may need to be designed to meet the specific needs of the critically ill patient.

Personalized physiological medicine

Conventional personalized medicine based on genetic profiling and pharmacological biomarkers will need development if they are to be applied to the practical needs of the critically ill patient. The main challenges of this form of personalized medicine will be to obtain genetic and biomarkers in a semicontinuous manner and to link this information to specific organ function allowing targeted therapy to be realized. The genetic profile and
transcription factors of the critically ill patient continuously change over time [3]. Levels of pharmacological biomarkers also change continuously over time [4], and the currently available biomarkers of sepsis have been found to lack specificity and sensitivity [5]. These aspects of conventional personalized medicine have prompted the idea that considering physiological variables as biomarkers may provide an essential addition to the needs of the critically ill patient because they relate more closely to the aims of intensive care medicine in terms of providing physiological recovery and organ support [6, 7]. Such a physiological approach to personalized medicine must be focused on the phenotype of the patient as well as on the functional properties of their organs and ultimately their cells as they change over time in response to disease and therapy. From this perspective, I propose here the concept of personalized physiological medicine as being more appropriate in achieving these aims. In doing so, I identify four pillars of personalized physiological medicine on which this concept is based (Fig. 1): 1) fitness and frailty; 2) organ function and response to therapy; 3) hemodynamic coherence; and 4) integration and feedback.

Pillar I: fitness and frailty
The first pillar of personalized physiological medicine is the assessment of fitness and frailty of the patient to determine their physiological reserve. Although obviously not applicable to critically ill patients, the gold standard for determining fitness is cardiopulmonary exercise testing (CPT), in which cardiovascular stress is imposed by incremental amounts of work and maximum oxygen consumption. Consequently the aerobic threshold is considered as the best index of cardiorespiratory fitness [8] but this has not been applied to critically ill patients. Inadequate exercise has been shown to be a risk factor for sepsis mortality, particularly in diabetics [9]. Exercising critically patients using a bedside cycle ergometer has been shown in survivors to result in improved 6-min walking distance, isometric quadriceps force, and the subjective feeling of well-being following discharge [10]. In experimental studies in septic rats, exercise protected organs from damage and lowered inflammatory mediators [11]. Increasingly, muscle is being recognized as a key hormone secreting organ where myokines, hormones secreted by the exercising muscle, are being shown to play a central role in resolving a host of disease states including cancer and diabetes [12]. Indeed, Montgomery and colleagues demonstrated that muscle wasting during critical illness is directly related to organ failure [13]. That is why developing objective measures of fitness in bed-ridden patients and maintenance of muscle mass by developing exercise modalities during critical illness must be recognized as an important aim in this pillar of personalized physiological medicine.

Extended lack of fitness can translate into frailty, a condition in which homeostatic mechanisms begin to fail, resulting in reductions in the physiological reserve of the neural, renal, skeletal, respiratory, cardiovascular, endocrine, immune, and coagulation systems when challenged by stress [14], such as in critical illness. Several studies have identified phenotypes associated with frailty, including measures related to physical activity, energy, nutritional status, strength, and cognition [15, 16]. The evaluation of frailty as a phenotype in the critically ill patient has been shown in several studies to be of special relevance in the prediction of intensive care unit (ICU) survival (e.g., [17]); frail survivors of critical illness have been shown to experience greater impairment in health-related quality of life and disability compared with those who are not frail [18]. Frailty, defined as a physiologic loss of reserve capacity and resistance to stressors [16, 19], has been quantified in several studies [15]. It is clear that continuous measures of fitness, frailty, and physiological reserve, along with coexisting comorbidity and primary disease, are key input variables defining the phenotype of the patient and therefore represent the first pillar of personalized physiological medicine.

Pillar II: organ function
The second pillar of personalized physiological medicine involves the function of the organ systems and their response to therapy. Evaluation of the regulatory capacity of the organ systems to stress factors is central because a loss of this regulatory capacity occurs in advance of physical injury to the parenchymal cells associated with upregulation of conventional pharmacological biomarkers. Loss of regulatory capacity represents a window of opportunity for treatment prior to the occurrence of irreversible injury requiring long-term regeneration [6]. Here, providing a physiological challenge to the patient and measuring organ response at the bedside is a central concept in evaluating physiological reserve. For instance, the dobutamine challenge test to evaluate the regulatory capacity of the β-adrenergic system in septic patients was introduced by Vallet and coworkers, who were able to predict survival in septic patients by measuring the response to oxygen delivery, consumption, and extraction [20]. A nonpharmacological version of the dobutamine stress test was explored by Kimmoun et al. to assess the efficiency of cardiac adaptation to septic shock by measuring cardiac contractility reserve-related parameters, including cardiac index, double product, and cardiac power index during the resuscitation procedure [21]. In this context, the heart rate response is also a promising methodology to assess the ability of the autonomic nervous system to
regulate cardiovascular responses and assess interorgan communication [22, 23]. The future challenge will be how to therapeutically treat the regulatory capacity of the β-adrenergic system to improve outcome.

Achieving optimal ventilation recruitment and avoiding ventilator-induced lung injury are arguably the main targets in achieving good ventilation-perfusion matching and gas exchange during mechanical ventilation. Adjustment of ventilator settings, assessing deleterious effects of often-used therapy, including fluid therapy and mechanical ventilation, and evaluating the direct effects of therapies directed at the lung itself, such as nebulization of antibiotics [24], anticoagulants [25], anti-inflammatory [26] and vasoactive compounds [27], truly requires a personalized approach in which bedside lung function evaluation is essential. Although several lung function parameters are available at the bedside (e.g., airway resistance, tidal volume, end-expiratory lung volume, intrinsic positive end-expiratory pressure (PEEP), compliance, dead space, and volumetric capnography) and novel clinical methodologies such as electric impedance tomography are being developed [28], essential lung function parameters directly related to the capacity of the lung to achieve gas exchange are lacking. A need

---

**Fig. 1** The four pillars of personalized physiological medicine. Pillar I is measurement of the fitness and frailty of the patient and their physiological reserve and fitness to deal with the physiological stress of critical illness. Pillar II concerns measurement of the function of organ systems and their response to therapy as well as their functional capacity and reserve including the immunological, humoral and coagulatory systems. Pillar III concerns the measurement of the hemodynamic coherence between the macro- and microcirculation and parenchymal cells in response to resuscitation. The loss of hemodynamic coherence can be identified by observation of the microcirculation, where type 1 concerns inflammation and infection-induced heterogeneous obstructions of microcirculatory flow, type 2 concerns hemodilution-induced loss of red blood cell filled capillaries, type 3 concerns microcirculatory stasis induced by excessive vasopressor load or raised venous pressures, and type 4 concerns tissue edema (red cells are well oxygenated and blue cells are hypoxic cells; taken from [35] with permission). Pillar IV is the integration and feedback of the various elements of the personalized physiological medicine modules to provide input in an integrative and time variant holistic manner to identify and assess the success of therapy and severity of organ and cellular dysfunction, as well as identifying the essential parameters in need of correction.
exists for the quantitative assessment of functional residual capacity (FRC), inhomogeneity of ventilation, and ventilation-perfusion matching. Indeed the importance of such measurements have been demonstrated in experimental models of acute lung injury (ALI) where the effects of respiratory movements could be directly observed in exposed mice lungs using dark-field intravital microscopy [29]. Measurement of these parameters has classically required the quantitative measurement of the washout of inert indicator gases requiring the use of complex mass spectrometry [30] at the bedside [31]. More practical measurement of these parameters at the bedside is currently under investigation (e.g., [32]). In addition to these volumetric measures, more comprehensive physical properties of the lung tissue itself are required beyond conventional dynamic compliance and airway resistance measures. Such information can be obtained, for example, by the forced oscillation technique in which the frequency-dependent impedance of the complete pulmonary system can be obtained, providing detailed information about the mechanical properties of the lung (e.g., [33]). It is clear from these considerations that there is a need to further develop techniques to measure these pulmonary parameters and to integrate them into a single monitoring platform to meet the requirements of this pillar of personalized physiological medicine.

Measuring kidney function is a specific challenge in intensive care management. This has typically been limited to the measurement of urine production and creatinine levels, both of which are considered inadequate indicators of kidney function. As a result, there has been a surge in renal pharmacological biomarker research. Although these biomarkers have been effective in identifying renal injury, they have not yet proven successful in guiding therapy. Their time-variant changes and their sensitivity only to advanced renal injury led us to develop the concept of physiological biomarkers of acute kidney injury (AKI) [6]. We proposed that such physiological biomarkers be related to renal hemodynamics and regulation, microcirculation and oxygenation, and tubular function because these are expected to be altered in advance of an injury, thereby identifying a window of therapeutic efficacy. Consistent with these concepts, Ronco and co-workers developed methodologies to measure renal physiological reserve, which was defined as the capacity of the kidney to increase the rate of glomerular filtration in response to a physiological stress; they proposed the administration of a fixed protein load for this purpose [34]. Using a similar concept to measure the functional capacity of the kidney, Chawla and co-workers administered furosemide to stimulate urine production and found that the furosemide stress test was much more sensitive in predicting stage 3 AKI than pharmacological biomarkers [35]. From these examples it is clear that there is a concerted effort to establish a functional platform to more comprehensively monitor organ function and assess the capacity to regulate functional reserve in real time as an essential goal for personalized physiological medicine. Recent advances in ultrasound such as contrast-enhanced ultrasound may make such sensitive monitoring of the renal microcirculation feasible in patients [36].

Pillar III: hemodynamic coherence

Resuscitation aims at normalizing systemic hemodynamic variables, such as stroke volume or blood pressure, with the expectation that a parallel improvement will occur in the perfusion and oxygenation of the microcirculation feeding the tissue beds of the organ systems. Homeostatic coupling between the systemic circulation and the microcirculation is essential for such an expectation to be met; in addition to the primary disease, resuscitation fluids and medications themselves can adversely affect this regulation. We have termed the required coupling between the macro- and microcirculation essential for successful resuscitation based on the correction of systemic hemodynamic variables as “hemodynamic coherence” [37]. Loss of hemodynamic coherence can occur if the factors affecting the microcirculation are not corrected by the resuscitation procedure focused on correction of the macrocirculation by resuscitation following shock. Such factors affecting the microcirculation can include immunological and/or factors affecting endothelial, leucocyte, and red blood cell function. In this context, its manifestation should be regarded as a dynamic process depending on the interactions between disease, therapy, and time. Whether the correction of systemic hemodynamic variables achieves adequate microcirculatory and tissue perfusion is often unknown and may manifest at the bedside as the patient being unresponsive. Such a situation prompts the clinician to administer even more fluids and medications, potentially causing harm. Assessment of the presence or absence of hemodynamic coherence requires the simultaneous measurement of the response of the macro- and the microcirculation. The microcirculation can be effectively visualized in the sublingual area using hand-held vital microscopy (e.g., [38]), which allows the parallel improvement in the microcirculation to resuscitation efforts based on the response of systemic parameters to be verified [39]. Identification of the presence or absence of hemodynamic coherence and the response of the microcirculation to therapy forms the third pillar of personalized physiological medicine because it assesses the physiological coupling between the various compartments in the hierarchy of the circulation to achieve uniform resuscitation. Loss of hemodynamic coherence at
the level of the microcirculation can be divided into four
types (Fig. 1). Type 1 loss of hemodynamic coherence is
characteristic of states of sepsis, in which inflammatory
mediators and oxidative and nitrosative stress factors
cause endothelial and erythrocyte injury resulting in
obstruction of the capillaries. This causes a heterogenic
microcirculatory flow and functional shunting in
parts of the microcirculation, resulting in reduced oxy-
gen extraction capacity characteristic of sepsis [40]. Type
2 loss of hemodynamic coherence occurs when an
excessive volume of fluids is given in an attempt to cor-
crect systemic variables, such as stroke volume and blood
pressure. While systemic variables may be normalized,
hemodilution causes reduced viscosity and dilution of
the blood, both of which cause a reduction in capillary
filling. This increases the diffusion distances between
oxygen-carrying erythrocytes and tissue cells, thereby
reducing the oxygen delivery capacity of the microcircu-
lation and its oxygen extraction capacity [39]. Type 3
loss of hemodynamic coherence is the condition where
high levels of vasopressors intended to improve blood
pressures can paradoxically cause constriction of micro-
circulatory blood flow [41]. Similarly, microcirculatory
impediment of flow can occur when high venous pres-
sures are targeted, resulting in microcirculatory flow
restriction due to tamponade [42]. Type 4 loss of
hemodynamic coherence occurs as a result of edema
(e.g., in burns [43] and in malaria [44]) in which leaky
vessels also cause increased diffusion distances and a
reduction in oxygen extraction.

Pillar IV: feedback and integration
Personalized physiological medicine directly relates to
the practice of intensive care in supporting organ func-
tion and restoring homeostasis. Concepts from systems
and control engineering, in which integration and feed-
back are central for the control of complex systems [22],
are important to consider. To this end, I define the
fourth pillar of personalized physiological medicine as
the integration of the modules in the aforementioned
three pillars to provide feedback on the functional activ-
ity of different physiological compartments, to identify
the functional state and stability of the system, and to
provide practical feedback to guide therapy and ensure
resolution of the unstable patient prior to the develop-
ment of irreversible states of critical illness.

Intensivists are confronted with an overwhelming
amount of patient data, including historical clinical
information as well as continuous online data regarding
the condition of the patient, which changes from
moment to moment [45]. Decisions based on assessment
of these data are based on clinical experience as well as
evidence from trials and knowledge of the literature;
however, this assessment relies more on the subjective
judgment of the physician rather on a strict analysis of
data. Various initiatives have been formulated to
integrate and simplify the vast amount of data being
generated from the patient, describing both the condi-
tion of the patient (e.g., APACHE, SAPS and SOFA) and
that of specific organ systems (e.g., AKIN and KDIGO
for AKI). Currently, more sophisticated predictive meth-
odologies are being developed, making use of complex
mathematics such as chaos and complexity theory [46].
Almost without exception, these methods are used to
evaluate the severity of disease without providing any
insight into the physiologic basis for the condition of the
patient. These approaches neither identify a given
physiological parameter in need of correction nor iden-
tify optimal therapy and provide feedback for a thera-
peutic maneuver in a goal-directed manner.

For these reasons, the fourth pillar of personalized
physiological medicine requires not only a predictive
environment to describe the condition of the patient,
but a more comprehensive mathematical model directly
related to the function of the organ systems from a sys-
tems engineering and integrative systems physiological
perspective. Here, measuring the interactions between
the various physiological compartments, including the
immune and humoral systems as well as the cellular and
ultimately even the genetic profile, stemming from the
previous three pillars of personalized physiological medi-
cine should provide a holistic description of the physio-
logical state of the patient and, more importantly,
provide practical feedback for identifying the need,
response, and success of therapy. Such an approach
requires adaptive modeling in which the model is con-
tinuously responding, considering time-variant changes
and providing an optimal model for patient care (e.g.,
[47]). Central to the model should be the measures of
organ function of pillar 2 to provide the needed feedback
to evaluate organ and therapy support and interactions
between the different physiological compartments. In
this way, the model should be capable of assessing the
stability of the system so that successful weaning from
an assisted mode can be accomplished, in which therapy
and organ-supporting devices are successful in achieving
eventual independent organ function. It can even be
conceived that such models can become closed loop
control systems for control of specific parts of the
support system (e.g., [48]).

Conclusion
Personalized medicine is a developing trend for the
future of intensive care medicine. However, the practical
implementation of this concept, if limited to the use of
genetic screening and pharmacological biomarkers, how-
ever appealing, is still in need of considerable develop-
ment. I therefore propose a personalized physiological
approach which I argue is much more suited to the requirements of critically ill patients. I have presented four pillars of personalized physiological medicine to address the full spectrum of this idea. This classification allows a modular approach, as its various aspects are under development in sometimes unrelated areas of critical care medicine. Integration of the concepts will provide a true challenge for the future, requiring collaboration between clinicians, physiologists, and engineers; the realization of bedside instruments to practice personalized physiological medicine remains a real challenge to industry. Nevertheless, I anticipate that the road map outlined in this paper may provide a conceptual framework within which critically ill patients will benefit from the promises of personalized medicine.

Acknowledgements
The author wishes to thank Prof. Diedrik Gommers of the Dept. of Intensive Care, Erasmus Medical Center, for valuable comments concerning this paper and Yasin Ince for drawing Fig. 1.

Funding
None declared by the author. Publication of this supplement was supported by Fresenius Kabi.

Availability of data and materials
Not applicable to this paper.

About this supplement
This article has been published as part of Critical Care Volume 21 Supplement 3. 2017: Future of Critical Care Medicine (FCCM) 2016. The full contents of the supplement are available online at https://ccforum.biomedcentral.com/articles/supplements/volume-21-supplement-3.

Author’s contributions
The author conceived the paper and wrote it.

Ethics approval and consent to participate
Not applicable to this paper.

Consent for publication
Not applicable to this paper.

Competing interests
CI has received honoraria and independent research grants from Fresenius-Kabi (Bad Homburg, Germany), Baxter Health Care (Deerfield, Illinois), and AM-Pharma (Bunnik, The Netherlands). He has developed SDF imaging and is listed as the inventor on related patents commercialized by MicroVision Medical (MVM) under a license from the Academic Medical Center (AMC). He has been a consultant for MVM in the past, but has not been involved with this company for more than 5 years and holds no shares in this company. Braedius Medical, a company owned by a relative of CI, has designed a hand-held microscope called CytoCam-IDF imaging. CI has no financial relation with Braedius Medical of any sort, i.e., never owned shares, or received consultancy or speaker fees from Braedius Medical. CI hosts an internet site (https://microcirculationacademy.org) which offers services (e.g., training, courses, and analysis) related to clinical microcirculation.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published: 28 December 2017

References
1. Marini JJ, Vincent JL, Annane D. Critical care evidence—new directions. JAMA. 2015;313(9):893–4.
2. Christaki E, Giamarellos-Bourboulis EJ. The beginning of personalized medicine in sepsis: small steps to a bright future. Clin Genet. 2014;86:56–61.
3. Calvano SE, Xiao W, Richards DR, Feliciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF. A network-based analysis of systemic inflammation in humans. Nature. 2005;437(7061):1032–7.
4. Alge JL, Arthur JM. Biomarkers of AKI. A review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol. 2015;10:147–55.
5. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
6. Okusa MD, Jaber BL, Donah P, Duranteau J, Yang L, Murray PT, Mehta RL, Ince C. Physiologic biomarkers of acute kidney injury: a conceptual approach to improving outcomes. Contrib Nephrol. 2013;182:65–81.
7. Ferrer R, Artigas A. Physiologic parameters as biomarkers: what can we learn from physiologic variables and variation? Crit Care Clin. 2011;27:229–40.
8. Day JR, Rostizer HB, Coats EM, Skakic A, Whipp BJ. The maximally attainable VO2 during exercise in humans: the peak vs. maximum issue. J Appl Physiol. 2003;95:1901–7.
9. Williams PT. Inadequate exercise as a risk factor for sepsis mortality. PLoS One. 2013;8(12), e79344.
10. Burtin C, Clerckx B, Robbeets C, Ferdinand P, Langer D, Troosters T, Hermans G, Descramer M, Gosselink R. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med. 2009;37:2499–250.
11. Chen HH, Hsieh SY, Yang FL, Hsu YH, Lin CC. Exercise training attenuates septic responses in conscious rats. Med Sci Sports Exerc. 2007;39(3):435–42.
12. Whitham M, Febbraio MA. The ever-expanding myokinin: discovery challenges and therapeutic implications. Nat Rev Drug Discov. 2016;15(10):719–29.
13. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Retnakaye G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Aley CG, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Motham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310(150):1591–600.
14. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9888):752–62.
15. de Vries NM, Staal JB, van Ravensberg CD. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2011;10:104–14.
16. Fried LP, Tangen CM, Walston J, Harris IK, Anderson GL, Baker D, BlFixture and mortality for elderly medicare beneficiaries. J Am Geriatr Soc. 2015;63:1121–8.
17. Bagshaw SM, Stelfox HT, Johnson JA, McDermid RC, Rolfsen DB, Tsuyuki RT, Ibrahim Q, Majumdar SR. Long-term association between frailty and health-related quality of life among survivors of critical illness: a prospective multicenter cohort study. Crit Care Med. 2015;43:9373–82.
18. Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ. 2011;183(8):E847–94.
19. Vallat B, Chopin C, Curtis SE, Bernard A, Dupuis BA, Fournier F, Mehdoussi H, Leroy B, Rime A, Saire C, Herbog P, Her B. Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: a prospective, multicenter study. Crit Care Med. 1993;21:1868–75.
20. Kimmoun A, Ducrocq N, Mory S, Defalise R, Müller L, Perez P, Fay R, Levy B. Cardiac contractile reserve parameters are related to prognosis in septic shock. Biomed Res Int. 2013;2013:930673.
21. Stone DJ, Celis LA, Cotte E. Engineering control into medicine. J Crit Care. 2013;28:652.e1–7.
22. Schmidt H, Lotze U, Ghanem A, Anker SD, Said SM, Braun-Dullaars R, Otmanns G, Rose S, Buerke M, Müller-Werdan U, Werdan K, Rauchhaus M. Relation of impaired inter-organ communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome. J C. Crit Care. 2014;29(3):676–73.
23. Rouby JJ, Bouhemad B, Monsel A, Brisson H, Arbelot C, Lu Q. Antibiotics Study Group. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology. 2012;117(6):1364–80.
24. Glas GJ, Serpa Neto A, Horn J, Cochran A, Dixon B, Elamin EM, Faraklas I, Disselkla S, Miller AC, Schultz MJ. Nebulized heparin for patients under
mechanical ventilation: an individual patient data meta-analysis. Ann Intensive Care. 2016;6(1):33.

26. Santos AR, Heidemann SM, Walters HL, Delius RE. Effect of inhaled corticosteroid on pulmonary injury and inflammatory mediator production after cardiopulmonary bypass in children. Pediatr Crit Care Med. 2007;8(5): 465–9.

27. Gantner M, Moric J. Pulmonary vasodilators—treating the right ventricle. Anesthesiol Clin. 2008;26(2):337.

28. Blankman P, Shono A, Hermans BJ, Wesselius T, Hasan D, Gomers D. Detection of optimal PEEP for equal distribution of tidal volume by volumetric capnography and electrical impedance tomography during decreasing levels of PEEP in post cardiac-surgery patients. Br J Anaesth. 2016;116(6):862–9.

29. Tabuchi T, Nickles HT, Kim M, Semple JW, Koch E, Brochard L, Slutsky AS, Pries AR, Kuebler WM. Acute lung injury causes asynchronous alveolar ventilation that can be corrected by individual sighs. Am J Respir Crit Care Med. 2016;193:396–406.

30. Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008;34:994–1001.

31. Huygen PE, Gültuna I, Ince C, Zwart A, Bogaard JM, Feenstra BW, Bruining HA. A new ventilation inhomogeneity index from multiple breath indicator gas washout tests in mechanically ventilated patients. Crit Care Med. 1993; 21(8):1149–58.

32. Bikker IG, Holland W, Specht P, Ince C, Gomers D. Assessment of ventilation inhomogeneity during mechanical ventilation using a rapid-response oxygen sensor-based oxygen washout method. Intensive Care Med Exp. 2014;2(1):14.

33. Dellacà RL, Zannin E, Ventura ML, Sancini G, Pedotti A, Tagliabue P, Misericocchi G. Assessment of dynamic mechanical properties of the respiratory system during high-frequency oscillatory ventilation. Crit Care Med. 2013;41(11):2502–11.

34. Sharma A, Zaraagouz JL, Gilbert RA, Ribeiro LC, Villa G, Ribeiro LC, Lu R, Sartori M, Faggiana E, de Cal M, Visscher GM, Corradi V, Brocca A, Husain-Syed F, Virendran A, Ronco C. Optimizing a kidney stress test to evaluate renal functional reserve. Clin Nephrol. 2016;86(7):18–26.

35. Koyner JL, Davison DL, Brasha-Mitchell E, Chalikonda DM, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Bennett MR, Kimmel PL, Seneff MG, Chawla LS. Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol. 2015;26(8):2023–31.

36. Wang Y, Beerbaum E, Ghanbari M, Qiu J, Ausems MEG, van der Schans CP, Miserocchi G. Assessment of dynamic mechanical properties of the respiratory system during high-frequency oscillatory ventilation. Crit Care Med. 2013;41(11):2502–11.

37. Dubin A, Pozo MO, Casabella CA, Pálizas Jr F, Murias G, Moseinco MC, Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol. 2015;26(8):2023–31.

38. Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19:58–13.

39. Aykut G, Veenstra G, Scorcella C, Ince C, Boerma C. Cytocam-IDF (incident dark field illumination) imaging for bedside monitoring of the microcirculation. Inten Care Med Exp. 2015;3:4.

40. Ince C. The rationale for microcirculatory-guided fluid therapy. Curr Opin Crit Care. 2014;20(3):301–8.

41. Ince C, Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Medicine. 1999;27(1369–77.

42. Dubin A, Pozo MO, Casabella CA, Pálizas Jr F, Murias G, Moseinco MC, Kanoore Edul VS, Pálizas F, Estenssoro E, Ince C. Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care. 2009;13(3):R92.

43. Vellinga NA, Boerma EC, Koopmans M, Donati A, Dubin A, Shapiro NI, Pease RM, Machado FR, Fries M, Akansu-Ayaoglu T, Pranskusas A, Hollenberg S, Balestra G, van Iterson M, van der Voort PH, Sadaka F, Miento G, Ayvar U, Hurtado FJ, Martinelli G, Payen D, van Haren F, Holley A, Pattnaik R, Gomez H, Mehta RL, Rodriguez AH, Ruiz C, Canales HS, Duranteau J, Spronk PE, Jhrunji S, Hubble S, Chierego M, Jung C, Martin D, Sorbara C, Tijssen JG, Bakker J, Ince C, 1. International study on microcirculatory shock occurrence in acutely ill patients. Crit Care Med. 2015;43:48–56.

44. Hemelkamp F, Klein H, Schmidt K, Vogelovol J, Kneser U, Kremer T. Microcirculatory effects of phystostigmine on experimental burn edema. J Burn Care Res. 2015;36(2):279–86.

45. Hanson JP, Lam SW, Mohanty S, Alam S, Pattnaik R, Mahanta KC, Hasan MU, Charunwatthana P, Mishra SK, Day NP, White NJ, Dondorp AM. Fluid resuscitation of adults with severe falciparum malaria: effects on acid-base status, renal function, and extravascular lung water. Crit Care Med. 2013; 41(4):972–81.